Maraviroc Amarox

Maraviroc, the active ingredient in Maraviroc Amarox, is a CCR5 antagonist presented as an oral tablet for oral use. It is indicated for the treatment of CCR5‑tropic HIV‑1 infection in adults, typically as part of combination antiretroviral therapy to suppress viral replication and improve immune function.

GNH USA supplies Maraviroc Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Maraviroc is used to treat infections that rely on the CCR5 co‑receptor pathway in HIV‑1 disease.

CCR5‑tropic HIV‑1 infection (treatment‑naïve patients): Used in combination regimens to achieve viral suppression. CCR5‑tropic HIV‑1 infection (treatment‑experienced patients): Added to existing therapy when resistance to other agents is present. CCR5‑tropic HIV‑1 infection (pre‑exposure prophylaxis research): Investigated as part of combination strategies to prevent acquisition of HIV.

Maraviroc may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: Mild to moderate intensity, often transient. - Nausea: May occur with or without vomiting. - Diarrhea: Usually self‑limiting. - Fatigue: Generalized tiredness reported by some patients. - Rash: Mild skin eruptions. - Dizziness: May affect balance.

Serious or Rare Side Effects: - Severe liver injury: Elevated transaminases or hepatitis. - Allergic reactions: Anaphylaxis, angioedema, or severe skin reactions such as Stevens‑Johnson syndrome. - Depression or mood changes: Monitor mental health. - Cardiovascular events: Rare cases of myocardial infarction. - Immune reconstitution syndrome: Worsening of opportunistic infections after immune recovery.

Before initiating Maraviroc, clinicians should consider several safety measures.

Liver function monitoring: Perform baseline and periodic liver enzyme tests. Cardiovascular assessment: Evaluate history of heart disease before initiation. Resistance testing: Confirm CCR5‑tropic virus prior to therapy. Hypersensitivity reaction: Discontinue if rash, swelling, or anaphylaxis occurs. Pregnancy and breastfeeding: Use only if potential benefit justifies potential risk. Store at ambient temperature below 25 °C: Keep in original packaging, protect from moisture and direct sunlight.

Maraviroc interacts with several drug classes; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase maraviroc plasma levels and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce maraviroc efficacy. - Protease inhibitors boosted with ritonavir: Can markedly elevate maraviroc concentrations.

Moderate Interactions (Monitor Closely): - Other antiretrovirals (e.g., efavirenz): May alter maraviroc levels. - Antacids containing aluminum or magnesium: May affect oral absorption. - Warfarin: Monitor INR for potential anticoagulant effect changes.